Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

Phase 1 Completed 15 enrolled University of California, Irvine

NaSingle-groupOpen-labelTreatment

Summary

This is a phase I clinical trial assessing the safety and recommended phase II dose of cabozantinib in combination with trifluridine/tipiracil (TAS102) in patients with metastatic colorectal carcinoma (mCRC).

Timeline

Start: 2021-07-16
Primary completion: 2023-08-29
Completion: 2024-04-09

Publications

Dayyani F, Balangue J, Valerin J, Keating MJ, Zell JA, Taylor TH, Cho MT. A Phase 1 Study of Cabozantinib and Trifluridine/Tipiracil in Metastatic Colorectal Adenocarcinoma. Clin Colorectal Cancer. 2024 Mar;23(1):67-72. doi: 10.1016/j.clcc.2023.11.001. Epub 2023 Nov 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cabozantinib	Small molecule	20 mg	Oral
Subject	Cabozantinib	Small molecule	40 mg	Oral
Subject	TAS-102	Small molecule	25 mg/m2	Oral
Subject	TAS-102	Small molecule	35 mg/m2	Oral

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

Summary

Timeline

Publications

Drugs

Indications